Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, ...
Zacks Investment Research on MSN
Nuvation Bio Inc. (NUVB) reports next week: Wall Street expects earnings growth
Wall Street expects a year-over-year increase in earnings on higher revenues when Nuvation Bio Inc. (NUVB) reports results ...
Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a late-stage immunotherapeutics company, today ...
Zacks Investment Research on MSN
What makes Korro Bio, Inc. (KRRO) a new buy stock
Korro Bio, Inc. (KRRO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...
Nuvation Bio Inc. (NYSE:NUVB) is one of the best stock picks of billionaire David Abrams. Nuvation Bio Inc. (NYSE:NUVB) is ...
View Nuvation Bio, Inc. Class A NUVB stock quote prices, financial information, real-time forecasts, and company news from CNN.
For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital ...
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Nuvation Bio Inc. (NYSE: NUVB). The investigation focuses on whether ...
Climb Bio appointed Dr. Perrin Wilson as Chief Business Officer to strengthen its leadership in developing immune-mediated disease treatments. Climb Bio, Inc. has announced the appointment of Dr.
Climb Bio, Inc. stays a Buy on budoprutug pMN data; Phase 2 PrisMN readout 2H 2026 + SLE/ITP upside and 2028 cash runway.
New program matches top researchers with expert service providers trained to offer a comprehensive suite of Shasta® ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results